IPSEY Financials: Ipsen S.A. AI Analysis



Financials

IPSEY Financial

Ipsen S.A.

0%

$0

At close: Jun 26, 16:00:00 GMT-4

0%

$0

Pre-market: Jun 29, 07:46:48 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

683

Dividend yield

EPS (TTM)

1.54

Market Cap

What is Ipsen S.A.?

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,358 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Features

Markets

News

Breakdown	TTM	12/31/2025	06/30/2025	12/31/2024	06/30/2024	12/31/2023
Revenue	3,929	1,992	1,937	1,822	1,751	1,683
Revenue Growth (YoY)	10%	9%	11%	8%	8%	2%
Cost of Revenue	750	425	325	302	316	301
Gross Profit	3,178	1,566	1,612	1,520	1,435	1,382
Selling, General & Admin	1,163	556	606	598	574	582
Research & Development	754	389	364	363	323	329
Operating Expenses	2,200	1,095	1,104	1,050	1,113	1,116
Other Non Operating Income (Expenses)	-39	-17	-21	-33	-23	-13
Pretax Income	578	153	425	142	289	500
Income Tax Expense	133	44	89	27	47	80
Net Income	443	109	334	113	232	449
Net Income Growth	28%	-4%	44%	-75%	19%	77%
Shares Outstanding (Diluted)	83.25	83.25	83.5	83.33	83.45	83.66
Shares Change (YoY)	0%	0%	0%	0%	0%	1%
EPS (Diluted)	5.31	1.31	4	1.36	2.77	5.36
EPS Growth	28%	-4%	44%	-75%	18%	75%
Free Cash Flow	827	475	352	242	-109	326
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	80.88%	78.61%	83.22%	83.42%	81.95%	82.11%
Operating Margin	24.89%	23.59%	26.17%	25.79%	18.33%	15.74%
Profit Margin	11.27%	5.47%	17.24%	6.2%	13.24%	26.67%
Free Cash Flow Margin	21.04%	23.84%	18.17%	13.28%	-6.22%	19.37%
EBITDA	1,603	899	702	960	536	198
EBITDA Margin	40.79%	45.13%	36.24%	52.68%	30.61%	11.76%
D&A For EBITDA	625	429	195	490	215	-67
EBIT	978	470	507	470	321	265
EBIT Margin	24.89%	23.59%	26.17%	25.79%	18.33%	15.74%
Effective Tax Rate	23.01%	28.75%	20.94%	19.01%	16.26%	16%

Breakdown

TTM

12/31/2025

06/30/2025

12/31/2024

06/30/2024

12/31/2023

Revenue

3,929

1,992

1,937

1,822

1,751

1,683

Revenue Growth (YoY)

10%

11%

Cost of Revenue

750

425

325

302

316

301

Gross Profit

3,178

1,566

1,612

1,520

1,435

1,382

Selling, General & Admin

1,163

556

606

598

574

582

Research & Development

754

389

364

363

323

329

Operating Expenses

2,200

1,095

1,104

1,050

1,113

1,116

Other Non Operating Income (Expenses)

-39

-17

-21

-33

-23

-13

Pretax Income

578

153

425

142

289

500

Income Tax Expense

133

Net Income

443

109

334

113

232

449

Net Income Growth

28%

-4%

44%

-75%

19%

77%

Shares Outstanding (Diluted)

83.25

83.5

83.33

83.45

83.66

Shares Change (YoY)

EPS (Diluted)

5.31

1.31

1.36

2.77

5.36

EPS Growth

28%

-4%

44%

-75%

18%

75%

Free Cash Flow

827

475

352

242

-109

326

Free Cash Flow Per Share

Gross Margin

80.88%

78.61%

83.22%

83.42%

81.95%

82.11%

Operating Margin

24.89%

23.59%

26.17%

25.79%

18.33%

15.74%

Profit Margin

11.27%

5.47%

17.24%

6.2%

13.24%

26.67%

Free Cash Flow Margin

21.04%

23.84%

18.17%

13.28%

-6.22%

19.37%

EBITDA

1,603

899

702

960

536

198

EBITDA Margin

40.79%

45.13%

36.24%

52.68%

30.61%

11.76%

D&A For EBITDA

625

429

195

490

215

-67

EBIT

978

470

507

470

321

265

EBIT Margin

24.89%

23.59%

26.17%

25.79%

18.33%

15.74%

Effective Tax Rate

23.01%

28.75%

20.94%

19.01%

16.26%

16%

Follow-Up Questions

What are Ipsen S.A.'s key financial statements?



According to the latest financial statement (Form-10K), Ipsen S.A. has a total asset of $0, Net loss of $0

What are the key financial ratios for IPSEY?



Ipsen S.A.'s Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Ipsen S.A.'s revenue broken down by segment or geography?



Ipsen S.A. largest revenue segment is Oncology, at a revenue of 2,545,000,000 in the most earnings release.For geography, United States is the primary market for Ipsen S.A., at a revenue of 1,210,300,000.

Is Ipsen S.A. profitable?



no, according to the latest financial statements, Ipsen S.A. has a net loss of $0

Does Ipsen S.A. have any liabilities?



no, Ipsen S.A. has liability of 0

How many outstanding shares for Ipsen S.A.?



Ipsen S.A. has a total outstanding shares of 0

Ipsen S.A. (IPSEY) Financial

IPSEY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Ipsen S.A.?

Ipsen S.A. (IPSEY) Financial

IPSEY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Ipsen S.A.?

IPSEY Income

Follow-Up Questions

What are Ipsen S.A.'s key financial statements?

What are the key financial ratios for IPSEY?

How is Ipsen S.A.'s revenue broken down by segment or geography?

Is Ipsen S.A. profitable?

Does Ipsen S.A. have any liabilities?

How many outstanding shares for Ipsen S.A.?